David Sinclair· PhD
Our OSK therapy extends lifespan of very old mice, suggesting it’s at least not harmful
Verbal pushback — no audited source on record.
86
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Our OSK therapy extends lifespan of very old mice, suggesting it’s at least not harmful
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
In vivo partial #reprogramming by OSKM expression is effective in delaying natural #aging-related molecular and physiological phenotypes
This week Davidsohn and colleagues showed our exact system extends lifespan in very old mice, when initiated at the human equivalent age of 70-80!
Just 2.5 weeks of OSKM reprogramming of young mice 🐁 increased age of death for the third quartile by 17%, with health benefits seen more than 2 years later 😮
Old mice (= human 80) treated with age reprogramming OSK therapy are healthier and longer lived 😯
Our new article reveals that gene therapy-mediated partial reprogramming extends lifespan and reverses age-related changes in aged mice, showcasing lifespan extension in wild-type animals through in vivo reprogramming.
“Here, we show that..an inducible OSK system in 124-week-old mice extends the median remaining lifespan by 109% and enhances several health parameters.”